Celastrol
(Cel), extracted from Tripterygium
wilfordii
Hook, is a potential antiobesity
drug, except for
its adverse reactions in clinic. In the present study, we synthesized
a promising celastrol–chitosan conjugate (Cel-CS1K) and evaluated
its antiobesity effect and biological safety in diet-induced obese
mice. Cel-CS1K showed higher drug loading (over 10 wt %), good solubility
(18–19 mg/mL) in water, slower peak time (T
max = 4 h), and clearance (T
1/2 = 8.97 h) in rats. Cel-CS1K effectively attenuated the cytotoxicity,
celastrol-induced apoptosis, and fat accumulation of hepatocytes.
Cel-CS1K reduced body weight and dietary amount same as the free Cel
but with lower toxicity in blood, liver, and testis. Cel-CS1K improved
the glucose homeostasis, HDL-C level, insulin sensitivity, and leptin
sensitivity, while it significantly reduced the gene expression levels
of LDL-C, TG, and TC in obese mice. Furthermore, the adipose-related
gene expression levels provided evidence in support of a role for
Cel-CS1K in losing weight by the multimode regulation. Overall, Cel-CS1K
provides a translatable therapeutic strategy for the treatment of
diet-induced obese humans.